Contact

What are you looking for?

CDISC Open Rules and CORE v1.0: A Milestone for Clinical Data Validation – Now Comes the Real Test

Clinical Research NewsNovember 18, 2026

The release of CDISC Open Rules and CORE v1.0 marks an important step toward consistent and transparent clinical data validation. Els Janssens, Data Management System and Process Manager at SGS and an active contributor to CDISC Open Rules since 2021, offers her perspective on what this means for pharma and biotech companies and why the real test begins now.

For years, pharmaceutical companies, CROs and technology providers have worked from the same published CDISC conformance requirements, yet those requirements could be interpreted and implemented differently in validation tools. The challenge was not necessarily the standards themselves, but the interpretation involved in turning them into executable validation checks. Different interpretations could therefore become embedded in validation tools, sometimes resulting in different findings for the same clinical study data.

Els Janssens

On November 3, 2026, CDISC released the first Open Rules packages, together with CORE v1.0, its first production-ready, open-source reference engine for executing them. Having contributed to CDISC Open Rules alongside her colleague Marisa Wyckmans, Els sees this as more than a technical milestone. It presents an opportunity to rethink how the industry approaches clinical data validation.

What changes with CORE v1.0?

Els sometimes compares the challenge of implementing CDISC conformance rules to recreating a family recipe. Imagine several family members trying to reproduce their grandmother's famous beef stew. They all know the ingredients and remember how it should taste, but without the exact recipe, each may make slightly different choices along the way. The results may all be good, but they won’t be quite the same.

That is essentially what has happened with data conformance rules. The requirements were published, but individual organizations and software providers had to interpret and translate them into machine-executable logic. Even with the same intentions, implementations could differ.

With CDISC Open Rules and CORE v1.0, we finally have a common recipe

CDISC Open Rules provides machine-executable conformance rules, while CORE is the open-source reference engine that runs them. The first production release supports rule packages for SDTMIG versions 3.2, 3.3 and 3.4, along with FDA Business Rules for SDTM.

Rather than relying on separate interpretations when turning published requirements into validation checks, organizations can now work from a common rule foundation. Importantly, the rules are open and transparent. Teams can examine how a rule is implemented and why a validation finding occurs, rather than rely entirely on a software tool's interpretation. For sponsors, this creates opportunities for more reproducible validation, greater consistency across validation solutions and clearer collaboration between internal teams, CROs and technology providers.

The rules are ready – now comes the real test

Through her involvement in CDISC Open Rules, Els has seen firsthand how much expertise goes into developing executable conformance rules. A requirement that appears straightforward on paper may be considerably more complex to translate into machine-executable logic. Interpreting the requirement, determining its applicability and addressing edge cases demand both technical knowledge and a thorough understanding of CDISC standards.

Els has seen how rules are developed. The structured and traceable process behind the rules, including the way they are reviewed and supported by test data and test evidence, gives her confidence in the foundation that has been created. But that confidence is only the starting point. The next challenge is to assess the rules across large volumes of diverse clinical study data. This will help identify scenarios that controlled testing may not have anticipated and reveal differences between the new rules and existing validation solutions.

One of the next steps following the release is a CDISC-governed industry pilot, where the Open Rules results will be tested and compared with those from existing validation solutions across a broad range of clinical study data. The pilot will provide broader evidence of how the rules perform across different studies and scenarios, helping to build industry confidence in their use.

The recipe is there, and Els trusts how it was created. Now the industry needs to cook with it.

Innovative Black Female Discussing a New Project Plan on Whiteboard

What does CORE v1.0 mean for pharma and biotech companies?

For sponsors, CORE v1.0 presents an opportunity to reassess their current clinical data validation processes.

Adopting CDISC Open Rules does not necessarily mean replacing existing validation systems or abandoning internal expertise. Instead, the rules provide a common foundation that organizations can incorporate into their own validation approaches and processes. This foundation can be extended with company-specific, sponsor-specific and study-specific checks.

At SGS, we see opportunities to incorporate CDISC Open Rules into our validation workflows while retaining the flexibility to address study or sponsor-specific requirements.

For sponsors considering implementation, three questions deserve attention:

  1. How do our existing validation checks compare with CDISC Open Rules? Identifying differences can reveal where interpretations or implementations may need further review.
  2. How should we integrate the rules into our current workflows? The right approach depends on existing systems, internal expertise and the organization's validation strategy.
  3. Which additional checks do we still need? CDISC Open Rules provide a common conformance foundation, but do not replace every sponsor- or study-specific quality requirement.

A shared foundation could reduce duplicated implementation and review effort, improve traceability and make validation knowledge easier to maintain across studies and partners. The objective is not simply to adopt another technology. It is to establish a more consistent, transparent and sustainable approach to clinical data validation.

Where could CDISC Open Rules take us in five years?

Looking ahead, Els expects CDISC Open Rules to change not only how validation checks are executed, but also how they are defined, published and maintained. Today, conformance requirements are still commonly distributed in documents or spreadsheets and require further interpretation before they become machine-executable.

She envisions a future where machine-executable rule specifications are created much closer to the development and publication of CDISC implementation guides themselves, with CDISC providing a governed source of truth for the rules and their expected behavior.

Multiple validation engines could execute the same rules, while organizations remain free to choose their technology and introduce company-specific or study-specific checks where needed. This could also support a shift toward earlier and more continuous validation throughout the clinical study lifecycle, rather than concentrating conformance checks primarily around submission preparation. Further development of rule packages, including ADaM and Define-XML, will be important steps toward that vision. We are not there yet. But CORE v1.0 provides a concrete foundation on which to build.

Ultimately, the success of CDISC Open Rules will be measured not by adoption alone, but by whether their use leads to more consistent, transparent and reliable clinical data validation across the industry.

News & Insights

  • SGS – Switzerland – Baar

Zugerstrasse 57,

6340, Baar, Switzerland